Drug Profile
Diphenhydramine orally dissolvable strips - Oak Therapeutics
Latest Information Update: 06 Jan 2022
Price :
$50
*
At a glance
- Originator Oak Therapeutics
- Class Antiallergics; Antiemetics; Antipruritics; Sedating antihistamines
- Mechanism of Action Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Allergy in USA (PO, Film)
- 04 Sep 2017 Preclinical trials in Hypersensitivity in USA (PO) (Oak Therapeutics pipeline, September 2017)